Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3370 Results for "
Complex
" in MedChemExpress (MCE) Product Catalog:
Products (3370)
3370 Results for "Complex" in MCE Product Catalog:
Cat. No.: HY-P83719
Synonyms: DKFZp459C139 antibody;
EC 3.4.25.1 antibody;
LMPX antibody;
Macropain epsilon chain antibody;
MB1 antibody;
MGC104214 antibody;
MGC118075 antibody;
MGC134464 antibody;
Multicatalytic endopeptidase Complex epsilon chain antibody;
Proteasome (prosome, macropain) subunit, beta type, 5 antibody;
Proteasome beta 5 subunit antibody;
Proteasome catalytic subunit 3 antibody;
Proteasome chain 6 antibody;
Proteasome epsilon chain antibody;
Proteasome subunit beta type-5 antibody;
Proteasome subunit MB1 antibody;
Proteasome subunit X antibody;
Proteasome subunit, beta type, 5 antibody;
Proteasome subunit, beta-5 antibody;
PSB5_HUMAN antibody;
PSMB5 antibody;
PSX large multifunctional protease X antibody;
X antibody
Cat. No.: HY-42163S
Target:
Research Areas:
3-((2S,5S)-5-(2-((2S,4R,6R)-6-(((2S,3S,4R,5R)-5-((S)-2,3-Bis((tert-butyldimethylsilyl)oxy)propyl)-4-methoxy-3-(tosylmethyl)te trahydrofuran-2-yl)methyl)-4-methyl-5-methylenetetrahydro-2H-pyran-2-yl)ethyl)-4-methylenetetrahydrofuran-2-yl)propan-1-ol-d3 It is a deuterated substance. 3-((2S,5S)-5-(2-((2S,4R,6R)-6-(((2S,3S,4R,5R)-5-((S)-2,3-Bis((tert-butyldimethylsilyl)oxy)propyl)-4-methoxy-3-(tosylmethyl)tetrahydrofuran-2-yl)methyl)-4-methyl-5-methylenetetrahydro-2H-pyran-2-yl)ethyl)-4-methylenetetrahydrofuran-2-yl)propan-1-ol is a complex organic molecule and a high-order synthetic intermediate.
Cat. No.: HY-180419
CAS No.: 1883721-73-0
Research Areas:
SF-3-030 is a potent, selective and non-ATP competitive ERK1/2 inhibitor. SF-3-030 selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling. SF-3-030 mitigates multiple features of asthma in a murine model of asthma. SF-3-030 can be used for the research of asthma and melanomasup .
Cat. No.: HY-L944
11028 compounds
MCE 18 stands for Medicinal Chemistry Evolution 2018. This metric was established based on structural data of 28,161 patented lead molecules, 1,370 marketed innovative drugs, and nearly 30,000 investigational candidates from preclinical to Phase III stages across 23 major global pharmaceutical companies from 1950 to 2018. After scaffold clustering analysis, a scoring model was constructed by integrating five three dimensional scaffold characteristics, including aromatic rings (AR), non aromatic heterocycles (NAR), chiral centers (CHIRAL), spirocycles (SPIRO), and the sp³ carbon ratio in cyclic and acyclic moieties, enabling quantitative assessment of molecular scaffold novelty and three dimensional complexity.
According to the score distribution of patented molecules, the top 25% of the original patent dataset was defined as the high novelty region. MCE 18 high scoring compounds selected based on this criterion can effectively avoid scaffold patent conflicts and intellectual property risks from the source. Molecules in this range typically feature a high sp³ carbon ratio, abundant chiral centers, spirocycles, and fused heterocycles with prominent three dimensional conformations. Their spatial properties allow precise matching to complex non traditional undruggable target pockets such as PPI interfaces and allosteric sites, making them ideal structural types for early stage screening of First in class drugs.
MCE‑18 Novelty Focused drug‑Like library strictly selects molecules from the aforementioned high scoring range, containing more than 10,000 premium drug like molecules with highly diverse scaffolds and rich 3D diversity. It can be used for high throughput screening of well established targets such as kinases, GPCRs, and proteases, and is especially suitable for hit identification in allosteric modulation, protein–protein interactions, and various undruggable orphan targets, fully supporting early stage drug discovery for cutting edge innovat
Cat. No.: HY-P702912
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: METTL3; Methyltransferase Like 3; Methyltransferase 3, N6-Adenosine-Methyltransferase Complex Catalytic Subunit; HMETTL3; MT-A70; CDNA FLJ58857, Highly Similar To N6-Adenosine-Methyltransferase 70 KDa Subunit; Spo8; CDNA FLJ57780, Highly Similar To N6-Adenosine-Methyltransferase 70 KDa Subunit; M6A; AdoMet-Binding Subunit Of The Human MRNA (N6-Adenosine)-Methyltransferase; N(6)-Adenosine-Methyltransferase Catalytic Subunit METTL3; N6-Adenosine-Methyltransferase Catalytic Subunit; MRNA (2'-O-Methyladenosine-N(6)-)-Methyltransferase; MRNA M(6)A Methyltransferase; N(6)-Adenosine-Methyltransferase 70 KDa Subunit; MTA70; N6-Adenosine-Methyltransferase 70 KDa Subunit; IME4; Methyltransferase-Like Protein 3
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P706076
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: MAP2K1; MAPKK1; Prev. PRKMK1; MAPKK 1; Dual Specificity Mitogen-Activated Protein Kinase Kinase 1; MEK 1; MAPK/ERK Kinase 1; Protein Kinase, Mitogen-Activated, Kinase 1 (MAP Kinase Kinase 1); MEK1; CFC3; MKK1; MEL; ERK Activator Kinase 1; Mitogen-Activated Protein Kinase Kinase 1; MAP Kinase Kinase 1; RAF1; Raf Proto-Oncogene Serine/Threonine Protein Kinase; Raf-1 Proto-Oncogene, Serine/Threonine Kinase; Non-Specific Serine/Threonine Protein Kinase; Raf-1; Eosinophil Cationic Protein; RAF Proto-Oncogene Serine/Threonine-Protein Kinase; Ribonuclease 3; Proto-Oncogene C-RAF; Oncogene RAF1; C-Raf; CMD1NN; CRAF; RNASE3; V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1; CRaf; C-Raf Proto-Oncogene, Serine/Threonine Kinase; NS5; V-Raf-1 Murine Leukemia Viral Oncogene-Like Protein 1; RAF
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P85907
Synonyms: 58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin Complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa Cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin Complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
Cat. No.: HY-P85984
Synonyms: 58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin Complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin Complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
Cat. No.: HY-P85597
Synonyms: 5''-deoxyribose-5-phosphate lyase Ku70; 5''-dRP lyase Ku70; 70 kDa subunit of Ku antigen; ATP dependent DNA helicase 2 subunit 1; ATP dependent DNA helicase II 70 kDa subunit; ATP-dependent DNA helicase 2 subunit 1; ATP-dependent DNA helicase II 70 kDa subunit; CTC box binding factor 75 kDa subunit; CTC box-binding factor 75 kDa subunit; CTC75; CTCBF; CTCBF; DNA repair protein XRCC6; G22P1; Ku 70; Ku autoantigen 70kDa; Ku autoantigen p70 subunit; Ku autoantigen, 70kDa; Ku p70; Ku70; Ku70 DNA binding component of DNA-dependent proteinkinase Complex; thyroid autoantigen 70 kDa; Kup70; Lupus Ku autoantigen protein p70; ML8; Thyroid autoantigen 70kD; Ku antigen; Thyroid autoantigen; Thyroid lupus autoantigen; Thyroid lupus autoantigen; Thyroid lupus autoantigen p70; Thyroid-lupus autoantigen; TLAA; TLAA; X ray repair complementing defective repair in Chinese hamster cells 6; X-ray repair complementing defective repair in Chinese hamster cells 6; X-ray repair cross-complementing protein 6; XRCC 6; XRCC6; XRCC6_HUMAN.
Cat. No.: HY-P705359
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility Complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A; HLA-Aw34.2 Antigen; HLAA; HLA-A-6802 Protein; Major Histocompatibility Complex Class I HLA-A-32 Protein; HLA-A-0203 Protein; HLA Class I Histocompatibility Antigen, A-1 Alpha Chain; MHC Class1 Antigen; HLA Class I Histocompatibility Antigen A Alpha Chain; Leukocyte Antigen; Signal Peptide Alpha1 And Alpha2 Domain; HLA-A26.4 Antigen; HLA Class I Histocompatibility Antigen; HLA-A10SA Antigen; MHC HLA-A Cell Surface Glycoprotein; MHC Class I HLA-A; HLA Class I A Locus Antigen A*68new; HLA-A26.3 Antigen; MHC Class I Human Leukocyte Antigen; HLA-A30.2 Antigen; Ig-Like Domain-Containing Protein; HLA-A2new Protein; MHC Class I Antigen Null Protein; Leucocyte Antigen; HLA-A Alpha1 And Alpha2 Domains; HLA-A9HH Antigen; MHC Class I Antigen Heavy Chain; MHC Class I Anti; Leucocyte Antigen A Alpha Chain; HLA-A29 Variant; Truncated MHC Class I Antigen; HLA-A25 Protein; Truncated MHC Class I Protein; MHC Alpha Chain; MHC Class I Antigen Precusor; HLA-A*02:01NEW; MHC Class I Protein (HLA-A); HLA-A Protein; HLA-A Locus Alpha 2 Domain; HLA Class I A; Lymphocyte Antigen M7-A2.2; Alpha1 Domain; MHC Class I Antigen R69772; MHC Class I; Human Leukocyte Antigen A; HLA-A*24var; HLA-A*24:02:01:01 Variant; HLA-A*0210; MHC Class I Antigen HLA-A; HLA-A*2903; Cell Surface Glycoprotein; HLA-A-6802; Leucocyte Antigen Class I; HLA-A-0203; Leukocyte Antigen Class I; HLA-A*3303; Transplantation Antigen; HLA-A*0218; HLA Class I Heavy Chain; HLA-A2 SLU; HLA-A11 Antigen A11.2; HLA-A-02; MHC Class I Antigen A; HLA-A-32; MHC Leukocyte Antigen; HLA-A30; MHC Class II Antigen; HLA-A25; MHC Class I Antigene; HLA-A26; Cell Surface Antigen; HLA-A*; HLA-A Alpha 1 Domain; HLA-A2; MHC Class I Antigen; A1102; MHC Class I Protein; Hla-A; HLA Class I Antigen; HLA-H; Leucocyte Antigen A; HLA_A; MCH Class I Antigen; HLA; B2M; Beta 2-Microglobulin; Beta-2-Microglobulin; Beta-2-Microglobin; Beta Chain Of MHC Class I Molecules; AMYLD6; Beta 2-Microglobulin Protein; MHC1D4; Human Nkt Tcr Alpha Chain; IMD43; Human Nkt Tcr Beta Chain
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
